FDA Approves Opdivo, Yervoy Combination For Kidney Cancer | Latest News RSS feed

FDA Approves Opdivo, Yervoy Combination For Kidney Cancer - Latest News


FDA Approves Immunotherapy Combination for Metastatic Colorectal Cancer

The Food and Drug Administration (FDA) approved the combination ... Opdivo (nivolumab) plus Yervoy (ipilimumab) for patients with previously treated microsatellite instability-high (MSI-H) or DNA mism... read more

FDA approves Opdivo-Yervoy combination for subset of patients with metastatic colorectal cancer

The FDA granted ... oncology (I-O) combination approved for these patients. “Bristol-Myers Squibb is pleased to bring forward Opdivo plus Yervoy as the first I-O/I-O combination therapy to be approved ... read more

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

The FDA granted an accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of adult ... metastatic colorectal cancer (mCRC) following progression on a f... read more

Looking for another news?


Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer

Bristol-Myers Squibb Company BMY announced that the FDA ... cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.Opdivo plus Yervoy is the first immu... read more


Opdivo + Yervoy Approved to Treat MSI-H/dMMR Metastatic Colorectal Cancer

The Food and Drug Administration has approved Opdivo (nivolumab; Bristol-Myers Squibb) in combination with Yervoy (ipilimumab ... metastatic colorectal cancer (CRC) that has progressed following treat... read more

FDA approves BMS' combo for colorectal cancer indication

The FDA approved Bristol-Myers Squibb's Opdivo, or nivolumab, 3 mg/kg, in combination with low-dose Yervoy, or ipilimumab, 1 mg/kg, as a treatment for patients ages 12 years and up who have certain ty... read more

Bristol-Myers Squibb's Opdivo-Yervoy combo wins right to challenge Merck's Keytruda in rare cancer

Tally another win for Bristol-Myers Squibb’s immunotherapy combination. Wednesday, the New Jersey drugmaker said its Opdivo-Yervoy ... the FDA had granted the drug a priority review in previously trea... read more

Bristol-Myers Squibb (BMY) Opdivo + Low-Dose Yervoy is First Immuno-Oncology Combination Approved for Some MSI-H/dMMR mCRC Patients

Today’s approved indication was based on data from the ongoing Phase 2 CheckMate -142 study evaluating the Opdivo + Yervoy combination ... at USC Norris Comprehensive Cancer Center. “The FDA’s approva... read more

Bristol-Myers Squibb’s immuno-oncology combo therapy, Opdivo receives US FDA approval for colorectal cancer

Bristol-Myers Squibb Company announced that its Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab ... of the study at USC Norris Comprehensive Cancer Center. “The FDA’s approval of an I-O/I- ... read more

BMS files Opdivo/Yervoy combo for lung cancer

“Lung cancer ... the FDA on the application is expected by February 20 next year. US regulators cleared a combination of Opdivo and Yervoy as a first-line treatment for patients with advanced renal ce... read more

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

It is difficult to predict where the combination will fall in the treatment paradigm, says Van Veldhuizen, but its FDA approval may provide physicians an alternative to the combination of nivolumab (O... read more

FDA OKs Bristol-Myers' Opdivo + Yervoy for first-line kidney cancer

The FDA approves Bristol-Myers Squibb's (BMY-8.4%) combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of patients with intermediate- and poor-risk advanced renal ce... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us